Search

Displaying results 4421 - 4430 of 6835 in total
  1. Drug

    Norethynodrel

    go.drugbank.com/drugs/DB09371
    Approved

    A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis.

  2. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide binds to the androgen receptor.

  3. Drug

    Panax notoginseng root

    go.drugbank.com/drugs/DB14304
    Investigational

    Panax notoginseng root is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: GONGFUTOUTANG Tou Tang Powder No. 3
  4. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ is in development for the treatment of moderate to severe pain, including cancer pain. … AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia

  5. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).

  6. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  7. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR-16 is under investigation by NeuroSearch.

  8. Drug

    KP1237

    go.drugbank.com/drugs/DB18401
    Experimental

    KP1237 is a antibody-redirecting molecule composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.

  9. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of Mycobacterium tuberculosis early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with rCFP-10.

  10. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to